3-methoxytyrosine has been researched along with Disease Exacerbation in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone." | 1.31 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishihara, A | 1 |
| Miyachi, T | 1 |
| Nakamura, T | 1 |
| Ohtsuki, T | 1 |
| Kimura, Y | 1 |
| Kihira, K | 1 |
| Yamawaki, T | 1 |
| Matsumoto, M | 1 |
| Pons, R | 1 |
| Ford, B | 1 |
| Chiriboga, CA | 1 |
| Clayton, PT | 1 |
| Hinton, V | 1 |
| Hyland, K | 1 |
| Sharma, R | 1 |
| De Vivo, DC | 1 |
| Liu, H | 1 |
| Iacono, RP | 1 |
| Schoonenberg, T | 1 |
| Kuniyoshi, S | 1 |
| Buchholz, J | 1 |
| Oechsner, M | 1 |
| Buhmann, C | 1 |
| Strauss, J | 1 |
| Stuerenburg, HJ | 1 |
1 review available for 3-methoxytyrosine and Disease Exacerbation
| Article | Year |
|---|---|
Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Aromatic-L-Amino-Acid Decarboxylases; Child; Child | 2004 |
3 other studies available for 3-methoxytyrosine and Disease Exacerbation
| Article | Year |
|---|---|
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Bensera | 2011 |
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Progressi | 1999 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech | 2002 |